Please provide your email address to receive an email when new articles are posted on . Bimzelx (bimekizumab-bkzx) is the first and only interleukin 17A and 17F inhibitor approved in this indication.

Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their ...

Pediatric patients with plaque psoriasis receiving apremilast vs placebo experienced significantly greater improvements in global disease activity and skin involvement. Treatment with apremilast was ...

Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.

Tildrakizumab showed significant clinical improvements, with 97.1% achieving Psoriasis Area Severity Index 75 (PASI75) and 82.9% reporting minimal impairment by week 28. The study involved 62 patients ...

THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (AMGN) today announced Otezla ® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug ...

Risankizumab improved visible psoriasis and reduced subclinical vascular inflammation on optical coherence tomography over 52 ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis Foundation ...

Working on fast cars has been Rogelio "Al" Castro's lifelong passion. Now, in retirement, he loves to take his grandkids to the speedway and tell them what it was like when he worked in the pit - the ...

Psoriasis symptoms can feel like a dark cloud hovering above your head. They’re pesky, sometimes even painful, making everyday life more difficult. Scalp psoriasis is a skin condition that causes the ...